Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Neoplasms 25Rectal Neoplasms 23Glioblastoma 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Breast Neoplasms 17Pancreatic Neoplasms 16Lung Neoplasms 16Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 14Neoplasms 12Oropharyngeal Neoplasms 11Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Adenocarcinoma Of Esophagus 8Uterine Cervical Neoplasms 7Glioma 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Gliosarcoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Melanoma 5Laryngeal Neoplasms 5Colorectal Neoplasms 5Xerostomia 4Sarcoma 4Mouth Neoplasms 4

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal Squamous Cell Carcinoma × Radiation × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡